Trial · NCT00443053
Results by group48
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 48
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With at Least on Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 47 | Fondaparinux 2.5 mg | 13 | participants | ||
| Number of Participants With at Least on Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 47 | Placebo | 88 | participants | ||
| Number of Participants With at Least One Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 77 | Fondaparinux 2.5 mg | 18 | participants | ||
| Number of Participants With at Least One Event of Venous Thromboembolism (VTE) and/or Death From Any Cause Recorded up to Day 77 | Placebo | 94 | participants | ||
| Number of Participants With at Least One Occurrence of Each Adjudicated Component of the Primary Efficacy Endpoint at Days (D) 47 and 77 | Fondaparinux 2.5 mg | Participants with at least one event, D 47 | 13 | participants | |
| Number of Participants With at Least One Occurrence of Each Adjudicated Component of the Primary Efficacy Endpoint at Days (D) 47 and 77 | Placebo | Participants with at least one event, D 47 | 88 | participants | |
| Number of Participants With at Least One Occurrence of Each Adjudicated Component of the Primary Efficacy Endpoint at Days (D) 47 and 77 | Fondaparinux 2.5 mg | Death, D 47 | 2 | participants | |
| Number of Participants With at Least One Occurrence of Each Adjudicated Component of the Primary Efficacy Endpoint at Days (D) 47 and 77 | Placebo | Death, D 47 | 1 | participants | |
| Number of Participants With at Least One Occurrence of Each Adjudicated Component of the Primary Efficacy Endpoint at Days (D) 47 and 77 | Fondaparinux 2.5 mg | Symptomatic PE, D 47 | 0 | participants | |
| Number of Participants With at Least One Occurrence of Each Adjudicated Component of the Primary Efficacy Endpoint at Days (D) 47 and 77 | Placebo | Symptomatic PE, D 47 | 5 | participants | |
| Number of Participants With at Least One Occurrence of Each Adjudicated Component of the Primary Efficacy Endpoint at Days (D) 47 and 77 | Fondaparinux 2.5 mg | Symptomatic DVT, D 47 | 3 | participants | |
| Number of Participants With at Least One Occurrence of Each Adjudicated Component of the Primary Efficacy Endpoint at Days (D) 47 and 77 | Placebo | Symptomatic DVT, D 47 | 18 | participants | |
| Number of Participants With at Least One Occurrence of Each Adjudicated Component of the Primary Efficacy Endpoint at Days (D) 47 and 77 | Fondaparinux 2.5 mg | Symptomatic recurrence of SVT, D 47 | 5 | participants | |
| Number of Participants With at Least One Occurrence of Each Adjudicated Component of the Primary Efficacy Endpoint at Days (D) 47 and 77 | Placebo | Symptomatic recurrence of SVT, D 47 | 24 | participants | |
| Number of Participants With at Least One Occurrence of Each Adjudicated Component of the Primary Efficacy Endpoint at Days (D) 47 and 77 | Fondaparinux 2.5 mg | Symptomatic extension of SVT, D 47 | 4 | participants | |
| Number of Participants With at Least One Occurrence of Each Adjudicated Component of the Primary Efficacy Endpoint at Days (D) 47 and 77 | Placebo | Symptomatic extension of SVT, D 47 | 51 | participants | |
| Number of Participants With at Least One Occurrence of Each Adjudicated Component of the Primary Efficacy Endpoint at Days (D) 47 and 77 | Fondaparinux 2.5 mg | Participants with at least one event, D 77 | 18 | participants | |
| Number of Participants With at Least One Occurrence of Each Adjudicated Component of the Primary Efficacy Endpoint at Days (D) 47 and 77 | Placebo | Participants with at least one event, D 77 | 94 | participants | |
| Number of Participants With at Least One Occurrence of Each Adjudicated Component of the Primary Efficacy Endpoint at Days (D) 47 and 77 | Fondaparinux 2.5 mg | Death, D 77 | 2 | participants | |
| Number of Participants With at Least One Occurrence of Each Adjudicated Component of the Primary Efficacy Endpoint at Days (D) 47 and 77 | Placebo | Death, D 77 | 1 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00443053/results